Sarcopenia and Myositis Revisited: Emerging Role of Fluorine-18 Fluorodeoxyglucose PET in Muscle Imaging.

Patrick Debs, Abdullah Al-Zaghal, Lilja B Solnes, Abass Alavi

Journal: PET clinics 2022;18(1):31-38

PMID: 36442964

Full Text on Elsevier Science View on PubMed

Abstract

Fluorodeoxyglucose (FDG) PET/computed tomography (CT) is a valuable diagnostic modality in the work-up of patients with suspected inflammatory myopathy. Sarcopenia and metabolic muscle activity on staging FDG PET/CT has been shown to correlate with overall survival in certain oncologic settings. Knowledge of the physiologic FDG uptake in skeletal muscles and optimization of imaging protocols are key for proper image analysis.

Address: The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21205, USA. Electronic address: https://twitter.com/PatrickDebs.; The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21205, USA. Electronic address: [email protected].; The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21205, USA.; Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.

DOI: 10.1016/j.cpet.2022.09.003

Link outs

Free resources

Medical:

https://medlineplus.gov/myositis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Fluorodeoxyglucose F18, Sarcopenia, Positron Emission Tomography Computed Tomography, Myositis, Positron-Emission Tomography, Muscle, Skeletal